New Haven, CT (PRWEB)
August 29, 2017
As part of a transformative effort to bring precision medicine to the bedside and the exam room, Yale New Haven Health System (YNHHS) of New Haven, Connecticut is adding ActX Genomic Decision Support to its Electronic Health Record, Epic.
The ActX platform includes evidence based clinical decision support content covering drug-genome interactions, hereditary genetic risks and carrier status. YNHHS will begin by integrating the ActX Genomic Decision Support for pharmacogenomics with the electronic health record used through its five hospitals and over 400 ambulatory sites, including the 1541 bed Academic Medical Center – Yale New Haven Hospital. This integration brings genomics to the bedside by leveraging the ActX service to enable real-time checking of each prescription against the patient’s genetic profile. Within their normal Epic order workflow, prescribers will receive alerts about potential adverse reactions, drug efficacy, or dosing based on the patient’s genetic findings. An embedded Genomic Profile for each patient will also be available within Epic.
The initial focus for real-time pharmacogenomics will be within behavioral health, cardiology, infectious disease, and pediatrics departments. By implementing the ActX genomic decision support service, YNHH will use the latest genetic knowledge to help its physicians choose the best medications for patients by avoiding adverse reactions and ineffective medications.
“Yale has been a pioneer in genomics and its applications for clinical use. Genomic health, where we can deliver actionable interpretations directly to clinical providers, is key to Yale New Haven Health’s vision for precision medicine. We plan to provide this valuable information directly to our physicians across the health system so we can continue to deliver the best care possible…